Inlyta 1 MG tablet 180S
Ended Awarded Last action
- Contract number
- SPE2DR26FDB9Q
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,566
Award facts
- Contract value 100% obligated
- $12,565.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,565.63 to AmerisourceBergen Drug Corp for the supply of Inlyta (axitinib) 1 mg tablets, a quantity of 180 units. This non-set-aside, firm fixed-price contract was awarded on January 27, 2026, with an ultimate completion date of February 18, 2026, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is a child contract issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a significant indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031. This prime IDC vehicle provides comprehensive pharmaceutical supply support for military healthcare systems and related federal medical institutions globally.
Inlyta is a tyrosine kinase inhibitor used primarily in oncology treatment, consistent with AmerisourceBergen's established role as a critical pharmaceutical distributor for federal healthcare procurement. The company's extensive portfolio of federal contracts demonstrates its capability to supply brand-name and generic medications, specialty pharmaceuticals, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations, the U.S. Coast Guard, and other government healthcare systems. This delivery order represents a routine pharmaceutical procurement supporting military medical treatment facilities and veteran healthcare programs through the established DLA pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FDB9Q?
SPE2DR26FDB9Q was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FDB9Q worth?
The government has obligated $12,566 on SPE2DR26FDB9Q.
Is contract SPE2DR26FDB9Q an order under another contract?
Yes. SPE2DR26FDB9Q is a delivery order under SPE2DR25D1100, an indefinite delivery contract.
Was contract SPE2DR26FDB9Q competed?
The extent of competition for SPE2DR26FDB9Q was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award